TYRUKO 300 mg/15mL
natalizumab-sztn · INJECTION · Sandoz Inc
No Recall History
Plain English
TYRUKO is a injection containing natalizumab-sztn at 300 mg/15mL, taken intravenous. Manufactured by Sandoz Inc.
Key Facts
- Brand Name
- TYRUKO
- Generic Name
- natalizumab-sztn
- NDC Code (Product)
61314-543- Manufacturer
- Sandoz Inc
- Strength
- 300 mg/15mL
- Dosage Form
- INJECTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761322
- Drug Class
- Integrin Receptor Antagonist [EPC]
- Marketing Start
- 11/17/2025
Recall History
No Recall HistoryFrequently Asked Questions
What is TYRUKO used for?
TYRUKO contains natalizumab-sztn. It is a injection taken intravenous. Consult your doctor for specific uses.
Is TYRUKO a controlled substance?
TYRUKO is not classified as a controlled substance by the DEA.
What is the generic name for TYRUKO?
The generic name for TYRUKO is natalizumab-sztn. There are no other listed brand versions of natalizumab-sztn.
What is the NDC code for TYRUKO 300 mg/15mL?
The NDC (National Drug Code) for TYRUKO 300 mg/15mL is 61314-543, listed by Sandoz Inc.
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)